imlunestrant
An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, imlunestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.
Synonym: | SERD LY3484356 |
---|---|
Code name: | LY 3484356 LY-3484356 LY3484356 |